Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations

The clinical development of Kirsten rat sarcoma virus (KRAS)-G12C inhibitors for the treatment of KRAS-mutant lung cancer is limited by the presence of co-mutations, intrinsic resistance, and the emergence of acquired resistance. Therefore, innovative strategies for enhancing apoptosis in KRAS-mutat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine 2024-06, Vol.5 (6), p.101578, Article 101578
Hauptverfasser:	Fukuda, Koji, Takeuchi, Shinji, Arai, Sachiko, Nanjo, Shigeki, Sato, Shigeki, Kotani, Hiroshi, Kita, Kenji, Nishiyama, Akihiro, Sakaguchi, Hiroyuki, Ohtsubo, Koshiro, Yano, Seiji
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apoptosis - drug effects Apoptosis - genetics azenosertib Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell Cycle Proteins - antagonists & inhibitors Cell Cycle Proteins - genetics Cell Cycle Proteins - metabolism Cell Line, Tumor CHK2 DNA damage response pathway G12C Humans Kirsten rat sarcoma KRAS Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mice Mice, Nude Mutation - genetics non-small cell lung cancer Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - metabolism sotorasib TP53 Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism WEE1 Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!